Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.059
Neutral
RSI(14)
46.341
Neutral
STOCH(KDJ)(9,3,3)
36.669
Neutral
ATR(14)
1.054
High Vlolatility
CCI(14)
-34.906
Neutral
Williams %R
57.368
Sell
TRIX(12,20)
-0.102
Sell
StochRSI(14)
71.250
Buy
Legend Biotech Corp
LEGN32.030USD
+0.440+1.39%
Close 11/11, 16:00（ET）Quotes delayed by 15 min
5.91BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Legend Biotech Corp
Currency: USD Updated: 2025-11-11Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Legend Biotech Corp's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
19
analysts
Buy
Current Rating
73.793
Target Price
+133.59%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Legend Biotech Corp Highlights
StrengthsRisks
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 436.08% year-on-year.
Overvalued
The company’s latest PE is -18.09, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 88.17M shares, decreasing 16.70% quarter-over-quarter.
Held by Matthews International Capital Management
Star Investor Matthews International Capital Management holds 1.03M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.18.
Financial Health
Currency: USD Updated: 2025-11-11The company's current financial score is 8.26, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 255.06M, representing a year-over-year increase of 36.74%, while its net profit experienced a year-over-year increase of 589.05%.
Score
Financials
6.53
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
7.06
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.69
Legend Biotech Corp's Company Valuation
Currency: USD Updated: 2025-11-11The company’s current valuation score is 7.24, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -18.09, which is -21.90% below the recent high of -14.13 and -126.67% above the recent low of -41.01.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 72/407
No Data
Earnings Forecast
Currency: USD Updated: 2025-11-11The company’s current earnings forecast score is 8.32, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Legend Biotech Corp is 74.00, with a high of 94.00 and a low of 53.12.
Score
Support & Resistance
No Data
Analyst Rating
Based on
19
analysts
Buy
Current Rating
73.793
Target Price
+133.59%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
521
Total
5
Median
6
Average
Company name
Ratings
Analysts
Legend Biotech Corp
LEGN
19
CRISPR Therapeutics AG
CRSP
30
Ionis Pharmaceuticals Inc
IONS
25
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
1
2
3
...
104
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-11-11The company’s current price momentum score is 6.59, which is lower than the Biotechnology & Medical Research industry's average of 6.78. Sideways: Currently, the stock price is trading between the resistance level at 34.21 and the support level at 30.43, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
31.960
Buy
MA10
32.076
Sell
MA20
32.245
Sell
MA50
32.933
Sell
MA100
35.351
Sell
MA200
34.713
Sell
Institutional Confidence
Currency: USD Updated: 2025-11-11The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.13. The latest institutional shareholding proportion is 47.77%, representing a quarter-over-quarter decrease of 1.59%. The largest institutional shareholder is Matthews International Capital Management, holding a total of 1.03M shares, representing 0.56% of shares outstanding, with 13.68% decrease in holdings.
Score
Institutional Shareholding
No Data
Risk Assessment
Currency: USD Updated: 2025-11-11The company’s current risk assessment score is 6.92, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.08. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.08
VaR
+4.68%
240-Day Maximum Drawdown
+36.61%
240-Day Volatility
+54.65%
Return
Best Daily Return
60 days
+5.06%
120 days
+11.18%
5 years
+19.64%
Worst Daily Return
60 days
-4.05%
120 days
-5.79%
5 years
-15.25%
Sharpe Ratio
60 days
-2.04
120 days
+0.52
5 years
+0.32
Risk Assessment
Maximum Drawdown
240 days
+36.61%
3 years
+63.80%
5 years
+63.80%
Return-to-Drawdown Ratio
240 days
-0.68
3 years
-0.17
5 years
+0.04
Skewness
240 days
+0.31
3 years
+0.66
5 years
+0.42
Volatility
Realised Volatility
240 days
+54.65%
5 years
+55.71%
Standardised True Range
240 days
+5.13%
5 years
+6.91%
Downside Risk-Adjusted Return
120 days
+108.53%
240 days
+108.53%
Maximum Daily Upside Volatility
60 days
+24.72%
Maximum Daily Downside Volatility
60 days
+22.60%
Liquidity
Average Turnover Rate
60 days
+0.41%
120 days
+0.41%
5 years
--
Turnover Deviation
20 days
-18.14%
60 days
+23.12%
120 days
+23.89%
Peer Comparison
Biotechnology & Medical Research
Legend Biotech Corp
LEGN
7.12 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Zymeworks Inc
ZYME
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
NewAmsterdam Pharma Company NV
NAMS
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insmed Inc
INSM
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
